Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Volume

<< Previous

Bullboard Posts

Next >>

Comment by Bookworm28on Aug 03, 2021 2:03pm

245 Views

Post# 33642936

RE:Volume

What do you figure? Is it time to put in a stink bid, or head for the hills?

I'm a little tempted to put in a stink bid, but I can't see this turning around in the near term. It reminds me of BLU in 2020 when their results didn't pan out. They're taking another shot at it, but the stock hasn't recovered. Is ATE going to be allowed to sign anyone up for a phase iii trial?

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario